Nifelat La (Nifedipine)

Nifedipine, the active ingredient in Nifelat La, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to manage high blood pressure, chest pain due to angina, and peripheral vascular disorders such as Raynaud's phenomenon.

GNH USA supplies Nifelat La as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory‑approved batches to qualified healthcare institutions.

Nifedipine is used to treat conditions that involve vascular smooth‑muscle constriction and elevated blood pressure.

Hypertension: lowers systemic blood pressure by dilating peripheral arteries. Angina pectoris: reduces myocardial oxygen demand by decreasing afterload. Raynaud's phenomenon: improves blood flow to extremities by relaxing digital arteries.

Nifedipine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: often transient and mild. - Flushing: warm sensation, especially on the face and neck. - Peripheral edema: swelling of ankles or lower legs. - Dizziness or light‑headedness, particularly on standing.

Serious or Rare Side Effects: - Severe hypotension: sudden drop in blood pressure requiring medical attention. - Myocardial infarction: rare but reported in susceptible patients. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Allergic reactions: rash, itching, or anaphylaxis.

When prescribing Nifedipine, clinicians should consider several safety measures.

Cardiovascular assessment: evaluate baseline blood pressure and heart rate before initiation. Concomitant beta‑blocker therapy: monitor for additive hypotensive effects. Liver impairment: adjust use in patients with severe hepatic dysfunction. Elderly patients: start with lower doses and observe for orthostatic symptoms. Pregnancy and lactation: use only if potential benefit justifies risk. Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and light.

Nifedipine can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase nifedipine plasma levels. - Grapefruit juice: can raise drug concentration leading to hypotension. - Concurrent use with other potent vasodilators (e.g., nitroglycerin): risk of severe hypotension.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt compensatory tachycardia, requiring blood pressure monitoring. - Diuretics: additive blood pressure‑lowering effect, monitor electrolytes. - Antihypertensive combination therapy: adjust dose to avoid excessive hypotension.